Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Jun. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue		$ 8,520	$ 16,924	$ 47,234	$ 40,010
Vaxcyte Agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue		656	1,592	2,149	2,970
Vaxcyte Agreements \| Research and Development Services
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue		563	636	1,860	1,707
Vaxcyte Agreements \| Materials Supply
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue		93	956	289	1,263
Collaboration and License Agreements and Supply Agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue		8,520	16,924	47,234	40,010
Collaboration and License Agreements and Supply Agreements \| Bristol-Myers Squibb Company ("BMS")
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue			189		5,591
Collaboration and License Agreements and Supply Agreements \| Astellas Pharma Inc. ("Astellas")
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue		7,661	9,988	43,798	23,593
Collaboration and License Agreements and Supply Agreements \| Tasly Biopharmaceuticals Co., Ltd. ("Tasly")
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue		32	5,072	1,007	5,072
Collaboration and License Agreements and Supply Agreements \| Vaxcyte
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue		656	1,592	2,149	2,970
Collaboration and License Agreements and Supply Agreements \| Ipsen Pharma SAS ("Ipsen")
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue		166		261
Collaboration and License Agreements and Supply Agreements \| Merck Sharp & Dohme Corporation ("Merck")
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue		5	83	19	2,776
Collaboration and License Agreements and Supply Agreements \| Merck KGaA, Darmstadt, Germany (operating in the United States and Canada under the name ''EMD Serono'')
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue					8
Astellas License and Collaboration Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue		7,661	9,988	43,798	23,593
Astellas License and Collaboration Agreement \| Ongoing Performance Related to Unsatisfied Performance Obligations
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue	$ 17,800	5,095	5,612	33,915	11,423
Astellas License and Collaboration Agreement \| Research and Development Services
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue		1,274	1,920	4,278	4,639
Astellas License and Collaboration Agreement \| Financing Component on Unearned Revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue		1,268	2,456	5,186	7,531
Astellas License and Collaboration Agreement \| Materials Supply
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue		24		419
Tasly License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue		32	5,072	1,007	5,072
Tasly License Agreement \| Contingent Payment
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue			5,000		5,000
Tasly License Agreement \| Research and Development Services
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue		32	$ 72	70	$ 72
Tasly License Agreement \| Materials Supply
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue				937
Ipsen Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue		166		261
Ipsen Agreement \| Research and Development Services
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue		93		111
Ipsen Agreement \| Materials Supply
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue		$ 73		$ 150